间期乳腺癌与干扰素免疫反应相关
研究分析672例浸润性乳腺癌患者,比较90例「真性」间期癌(乳腺X线密度<25%的低密度乳腺女性)与310例筛查检出肿瘤的基因表达差异,并校正PAM50亚型。基于47个基因构建间期癌基因表达谱(IC-Gx),在2270个乳腺肿瘤中验证其与干扰素反应相关免疫亚型的关联,并发现I类干扰素基因存在显著体细胞和胚系变异负荷。
要点
- 间期癌与8331个基因名义相关(P<0.05,倍数变化>1.5),免疫相关通路为关键改变过程。
- 基于47个最强关联基因(FDR<0.05)的IC-Gx主要与涉及干扰素反应的免疫亚型相关。
- 间期癌与干扰素基因的相互作用网络中,I类干扰素基因存在显著的体细胞和胚系变异负荷。
核心结论
- 研究识别了间期乳腺癌的新分子特征,突出干扰素通路作为预防或治疗的潜在靶点。
研究设计与样本
- 从672例浸润性乳腺癌患者中,分析90例「真性」间期癌(乳腺X线密度<25%的低密度乳腺女性)与310例筛查检出肿瘤的基因表达差异,并校正PAM50亚型。
- 在总计2270个乳腺肿瘤(不论间期癌状态)中计算间期癌基因表达谱(IC-Gx),并检验其与基于表达的乳腺癌免疫亚型的关联。
- 研究还探讨了遗传和体细胞基因变异在间期癌不同特征中的贡献。
主要发现
- 识别出8331个与间期癌名义相关的基因(P值<0.05,倍数变化>1.5)。
- 基因集富集分析显示免疫相关通路是间期癌中改变的关键过程。
- 基于47个最强关联基因(错误发现率<0.05)的IC-Gx主要与涉及干扰素反应的免疫亚型相关。
- 分离出间期癌与干扰素基因的相互作用网络,其中观察到I类干扰素基因的体细胞和胚系变异负荷显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aggressive nature of breast cancers detected between planned mammographic screens, so-called interval cancers, remains elusive. Here, we aim to characterise underlying molecular features of interval cancer. METHODS: From 672 patients with invasive breast cancer, we analysed gene expression differences between 90 'true' interval cancer cases (i.e. women with low-dense breasts defined as per cent mammographic density <25%) and 310 screen-detected tumours while accounting for PAM50 subtypes and thus overall tumour aggressiveness. We computed an interval cancer gene expression profile (IC-Gx) in a total of 2270 breast tumours (regardless of interval cancer status) and tested for association with expression-based immune subtypes in breast cancer. In addition, we investigated the contribution of inherited and somatic genetic variants in distinct features of interval cancer. RESULTS: We identified 8331 genes nominally associated with interval cancer (P-value < 0.05, fold-change > 1.5). Gene set enrichment analysis showed immune-related pathways as key processes altered in interval cancer. Our IC-Gx, based on 47 genes with the strongest associations (false discovery rate < 0.05), was found to be associated mainly with immune subtypes involving interferon response. We isolated an interaction network of interval cancer and interferon genes for which a significant load of somatic and germline variants in class I interferon genes was observed. CONCLUSION: We identified novel molecular features of interval breast cancer highlighting interferon pathways as a potential target for prevention or treatment.
引用
- Ugalde-Morales E, Grassmann F, Humphreys K, et al. Interval breast cancer is associated with interferon immune response. Eur J Cancer. 2022. PMID: 35026490. doi:10.1016/j.ejca.2021.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。